Serum interleukin 17 concentrations in dogs with immune-mediated hemolytic anemia
| Autor: | Shauna L. Blois, Geoffrey A. Wood, Christian Bédard, Anthony C. G. Abrams-Ogg, Benoît Cuq, Guy Beauchamp, R. Darren Wood |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Hemolytic anemia
medicine.medical_specialty 040301 veterinary sciences canine Inflammation autoimmune disease Standard Article 030204 cardiovascular system & hematology Gastroenterology 0403 veterinary science 03 medical and health sciences 0302 clinical medicine Dogs Internal medicine medicine Animals Dog Diseases Immune mediated hemolytic anemia Autoimmune disease General Veterinary business.industry Interleukin-17 04 agricultural and veterinary sciences Hematology medicine.disease Response to treatment Standard Articles cytokines inflammation Potential biomarkers Interleukin 17 Anemia Hemolytic Autoimmune SMALL ANIMAL medicine.symptom Autoimmune hemolytic anemia business Biomarkers |
| Zdroj: | Journal of Veterinary Internal Medicine |
| ISSN: | 1939-1676 |
| Popis: | Background Increased serum interleukin 17 (IL-17) concentration has been associated with the immunopathogenesis of autoimmune hemolytic anemia in humans. No data are available about IL-17 in immune-mediated hemolytic anemia (IMHA) of dogs. Objectives Monitor changes in serum IL-17 concentration during the acute stages of IMHA in dogs, compared with results in healthy dogs, and its relationship with outcome. Animals Thirty-one client-owned dogs with primary IMHA and 27 healthy dogs. Methods Quantification of serum IL-17 concentration using a commercially available ELISA kit at the time of admission (D0), after 48 hours (D2) and after 96 hours (D4) as compared to concentration in healthy dogs. The IMHA dogs were classified as survivors if discharged from hospital, or nonsurvivors for any cause of in-hospital mortality. Results Mean serum IL-17 concentration was higher in dogs with IMHA on admission compared with healthy dogs (D0), but this difference was not significant (mean, 19.52 pg/mL vs 10.52 pg/mL, respectively, P = .17). Throughout hospitalization, serum IL-17 concentration significantly decreased in survivors. Serum IL-17 concentration at D0 was not different between survivors and nonsurvivors, but surviving dogs had significantly lower serum IL-17 concentration at D2 and D4 (P = .04 and P = .004, respectively) compared with nonsurviving dogs. No correlation was found between serum IL-17 concentration and serum total bilirubin or lactate concentrations or CBC parameters. Conclusion and clinical importance Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text